Proactive | Interview with CEO Paul Anderson

23 February 2024
Posted in Media, Video
23 February 2024 Orthocell

Orthocell CEO Paul Anderson spoke with Jonathan Jackson at Proactive about the Company’s recent strategic placement of $3.5 million, adding prominent investors to the share register.

In the interview, he discusses how ample funding and a strong Board supports the Company as it advances its commercialisation plans for breakthrough nerve repair product, Remplir.

“This placement enables us now to freely drive these really exciting products – Remplir, in particular – into the US market. That takes us well through FDA approval, and really solidifies the position of the Company as we move into those US markets.”